蛋白质组学和放射蛋白质组学在肝癌生物标志物用于诊断、治疗及增强介入放射治疗方面的作用。

David Geffen School of Medicine, Department of Radiological Sciences, University of California Los Angeles, California, United States.

Cancer Rep Rev. 2025 Jun 5;8. doi: 10.15761/crr.1000244.

Hepatocellular carcinoma (HCC) is the most common liver cancer and is highly malignant. Current diagnostic tests are blood, imaging and biopsy, with no useful predictive biomarker. Additionally, targeted therapies are unavailable, which hinders the potential for personalized therapy in HCC patients. Here, we discuss the limited studies conducted thus far to identify molecular targets for early detection and treatment of HCC, their limitations and future directions in this field. However, the integration of multi-omics analyses, such as genomics, proteomics, and phosphoproteomics, has provided valuable insights into the mechanisms and pathways underlying the disease.

肝细胞癌（HCC）是最常见的肝癌，具有高度恶性。目前的诊断测试包括血液检查、影像学检查和活检，尚无有效的预测生物标志物。此外，靶向治疗无法应用，这阻碍了HCC患者个性化治疗的可能性。在此，我们讨论了迄今为止为确定HCC早期检测和治疗的分子靶点所进行的有限研究、它们的局限性以及该领域的未来方向。然而，多组学分析的整合，如基因组学、蛋白质组学和磷酸蛋白质组学，为该疾病的潜在机制和途径提供了有价值的见解。